Clinical Trial Update: Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) [Phase 2]

View source ↗

Summary

Phase 2b randomized trial of Tecemotide (L-BLP25) for non-small cell lung cancer completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecemotide (L-BLP25)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2015-11-18